Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up
These findings suggest that certain patients diagnosed as malignant gliomas, including G34-DHG (WHO grade 4), can acquire long-term survival after local immunotherapy. Tumor GTR before local immunotherapy and relatively weaker immunosuppressive tumor microenvironment are the favorable factors for long-term survival. Larger, controlled studies with standardized treatment protocols, including consistent use of GTR, are warranted to further evaluate the potential benefits of locally delivered immunotherapy.
Authors
- Ke Sai (ORCID: https://orcid.org/0000-0003-1762-9019)
- Jian‐Chuan Xia (ORCID: https://orcid.org/0000-0002-1268-3967)
- Ranyi Liu (ORCID: https://orcid.org/0000-0002-3986-0177)
- Xiangheng Zhang
- Hao Duan (ORCID: https://orcid.org/0000-0002-7078-8900)
- Yukun Chen (ORCID: https://orcid.org/0000-0001-5523-3942)
- Yonggao Mou (ORCID: https://orcid.org/0000-0001-6045-503X)
- Zhenqiang He (ORCID: https://orcid.org/0000-0001-9094-4897)
- Zhenghe Chen
- Wanming Hu (ORCID: https://orcid.org/0000-0002-3632-1258)
- Cheng Zou
- Yongqiang Li (ORCID: https://orcid.org/0000-0003-1551-3020)
- Zhongping Chen
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Immunology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s12865-024-00676-2
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.88
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province